PARP1 as a potential biomarker for response to immunotherapy

In a recent study, the researchers looked at the RNA in renal cell carcinoma (RCC) tissue samples from patients being treated with immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, avelumab) to try to identify a biomarker for response to treatment. They found that patients with low levels of a protein-coding gene called PARP1 (poly (ADP-ribose) polymerase […]

read more

Genetic profiling of renal medullary carcinoma paves the way for a potential treatment

Renal medullary carcinoma (RMC) is an aggressive cancer that mainly affects young people of African descent. It is resistant to all targeted agents used to treat other renal cell carcinomas (RCCs) and has limited therapeutic options. This study, published in the journal Cancer Cell analyses the genes of people with renal medullary carcinoma and finds […]

read more

PARP inhibitors, vaccines and combination therapies for kidney cancer

In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]

read more

Potential new treatments for kidney cancer discussed at 2019 Kidney Cancer Research Summit

In this interview from the 2019 Kidney Cancer Research Summit and published in the journal CURE, Dr Sumanta Pal, a medical oncologist at City of Hope, California, USA discusses the expanding field of kidney cancer treatment and what this means for patients with renal cell carcinoma (RCC). During the interview, Dr Pal discusses the use […]

read more
Showing all 4 results
  TOP